down arrow

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100006624
HKD
6.16
-0.34 (-5.23%)

Dec 16

HKG

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
Why is ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. ?
1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 0%
  • Poor long term growth as Net Sales has grown by an annual rate of 1,004.45% and Operating profit at 8.65% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2
Flat results in Dec 24
  • INTEREST(Q) Highest at HKD 2.19 MM
3
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 2.33%, its profits have risen by 16.1%
4
Underperformed the market in the last 1 year
  • The stock has generated a return of 2.33% in the last 1 year, much lower than market (Hang Seng Hong Kong) returns of 28.33%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
2.33%
-0.67
89.30%
Hang Seng Hong Kong
28.33%
1.10
25.87%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
1,004.45%
EBIT Growth (5y)
8.65%
EBIT to Interest (avg)
-254.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.93
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
5.77
EV to EBIT
-10.28
EV to EBITDA
-11.01
EV to Capital Employed
67.59
EV to Sales
43.45
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-657.21%
ROE (Latest)
-45.52%
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

Icon
Not enough Data to analyse Financial Trend
Icon
Not enough Data to analyse Financial Trend
Here's what is working for ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
Net Profit
Higher at HKD -171.88 MM
than preceding 12 month period ended Dec 2024
MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (HKD MM)

Debtors Turnover Ratio
Highest at 13.56% and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

EPS
Highest at HKD -0.43
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Cash and Eqv
Highest at HKD 800.42 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Debt-Equity Ratio
Lowest at -90.7 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd.
Interest
Highest at HKD 2.19 MM
in the last five periods and Increased by 42.02% (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (HKD MM)

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."